Compare
Jupiter Neurosciences, Inc. vs Bioadaptives, Inc. vs PRF Technologies Ltd. vs Impact Biomedical Inc.
| Latest fiscal year | Jupiter Neurosciences, Inc. JUNS | Bioadaptives, Inc. BDPT | PRF Technologies Ltd. PRFX | Impact Biomedical Inc. IBO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $21.8K | $18.3K | $17.0K | $32.0K |
| Revenue growth (YoY) | n/a | +44.3% | n/a | n/a |
| Gross margin | 80.6% | 68.4% | -311.8% (computed) | n/m (computed) |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$8.64M | -$1.56M | -$5.02M | -$11.84M |
| EPS (Diluted) | -$0.25 | -$0.15 | -$7.47 | -$0.38 |
| Operating cash flow | -$5.41M | -$516.0K | -$3.96M | -$1.89M |
| Free cash flow | n/a | -$534.0K | -$3.96M | n/a |
| Cash & equivalents | n/a | $215.2K | $3.12M | $3.0K |
| Total assets | $5.56M | $225.9K | $12.00M | $17.41M |
| Total liabilities | $7.40M | $2.36M | $2.71M | $1.85M |
| Shareholders' equity | -$1.83M | -$2.13M | $8.54M | $12.61M |
| Return on year-end equity | n/a | n/a | -58.8% | -93.9% |
| Shares outstanding | 34.45M | 12.01M | 830.6K | 104.62M |
Revenue, most recent five fiscal years
| Fiscal year | Jupiter Neurosciences, Inc. | Bioadaptives, Inc. | PRF Technologies Ltd. | Impact Biomedical Inc. |
|---|---|---|---|---|
| Latest | $21.8K Ended 2025-12-31 | $18.3K Ended 2025-12-31 | $17.0K Ended 2025-12-31 | $32.0K Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $12.7K Ended 2024-12-31 | $0 Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $28.6K Ended 2023-12-31 | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $17.2K Ended 2022-12-31 | n/a | $50.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $19.8K Ended 2021-12-31 | n/a | n/a |